SFDA grants approval for clinical studies to Benapenem

摘要

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company with the largest cardio-cerebral vascular ("CCV") drug franchise in China's prescription market, announced that the active pharmaceutical ingredients of and injection form ofBenapenem, being a Category 1.1 new drug developed by the KBP Biosciences Pharmaceutical Technical Co., Ltd, a wholly-owned subsidiary of Sihuan Pharmaceutical, received the Approval for Clinical Studies (2012L02703, 2012L02697) from the State Food and Drug Administration. Phase I of clinical studies are set to begin in the first half of this year. The drug has been patented in China and the United States. It is the third Category 1 innovative drug for which the Company has received Approval for Clinical Studies.